Sprint Bioscience Dirección

Dirección controles de criterios 2/4

El CEO de Sprint Bioscience's es Johan Emilsson, nombrado en Jan 2023, tiene una permanencia de 1.33 años. posee directamente un 0.029% de las acciones de la empresa, con un valor de €2.27K. La antigüedad media del equipo directivo y de la junta directiva es de 2.8 años y 4.3 años, respectivamente.

Información clave

Johan Emilsson

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	1.4yrs
Participación del CEO	0.03%
Permanencia media de la dirección	2.8yrs
Promedio de permanencia en la Junta Directiva	4.4yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Johan Emilsson (40 yo)

1.4yrs

Permanencia

Johan Emilsson is Chief Executive Officer of Sprint Bioscience AB (publ) from 2023. Johan Emilsson has broad experience in business development within the pharmaceutical industry and most recently from Fer...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Johan Emilsson	Chief Executive Officer	1.4yrs	sin datos	0.029% SEK 2.3k
Pär Nordlund	Founder	no data	kr25.00k	0.91% SEK 72.8k
Martin Andersson	Co-Founder & Chief Scientific Officer	15.4yrs	sin datos	0.39% SEK 31.2k
Kenth Hallberg	Founder & Director of Structural Chemistry	no data	sin datos	sin datos
Mathias Skalmstad	Chief Financial Officer	2.8yrs	sin datos	0.10% SEK 8.2k
Anne-Marie Wenthzel	Chief Business Officer	no data	sin datos	0.26% SEK 20.9k

2.8yrs

Permanencia media

53yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 5JA1 se considera experimentado (2.7 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Svein Mathisen	Independent Director	4.4yrs	kr140.00k	0.064% SEK 5.1k
Bjorn Sjostrand	Independent Chairman of the Board	3.4yrs	kr279.00k	1.26% SEK 100.7k
Lewis Cantley	Member of Scientific Advisory Board	no data	sin datos	sin datos
Rune Nordlander	Director	14.4yrs	kr140.00k	15.13% SEK 1.2m
Fredrik Lehmann	Independent Director	5.1yrs	kr140.00k	0.072% SEK 5.7k
Robert Devita	Member of Scientific Advisory Board	no data	sin datos	sin datos
Gunilla Enblad	Member of Scientific Advisory Board	no data	sin datos	sin datos
Karen From	Independent Director	1.1yrs	sin datos	sin datos

4.4yrs

Permanencia media

61.5yo

Promedio de edad

Junta con experiencia: La junta directiva de 5JA1 se considera experimentada (4.3 años de antigüedad promedio).

Sprint Bioscience Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

High number of new and inexperienced directors

Sprint Bioscience AB (publ) Appoints Erik Kinnman as New CEO in Place of Charlotte Leife

Recent updates

Full year 2023 earnings released: kr0.006 loss per share (vs kr1.43 loss in FY 2022)

Third quarter 2023 earnings released: EPS: kr0.41 (vs kr0.33 loss in 3Q 2022)

Second quarter 2023 earnings released: kr0.17 loss per share (vs kr0.45 loss in 2Q 2022)

Now 36% undervalued after recent price drop

Now 29% undervalued

Now 24% undervalued

Now 21% undervalued after recent price drop

Full year 2022 earnings released: kr1.43 loss per share (vs kr0.85 loss in FY 2021)

Third quarter 2022 earnings released: kr0.33 loss per share (vs kr0.54 profit in 3Q 2021)

Second quarter 2022 earnings released: kr0.45 loss per share (vs kr0.60 loss in 2Q 2021)

First quarter 2022 earnings released: kr0.36 loss per share (vs kr0.65 loss in 1Q 2021)

Sprint Bioscience Launches NIMA at BIO International

High number of new and inexperienced directors

Full year 2021 earnings released: kr0.85 loss per share (vs kr2.55 loss in FY 2020)

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Third quarter 2021 earnings released: EPS kr0.54 (vs kr0.36 loss in 3Q 2020)

Sprint Bioscience AB (publ) Adds New Cancer Drug Program to its Project Portfolio

Second quarter 2021 earnings released: kr0.60 loss per share (vs kr1.01 loss in 2Q 2020)

First quarter 2021 earnings released: kr0.65 loss per share (vs kr0.79 loss in 1Q 2020)

Sprint Bioscience AB (publ) announced that it has received SEK 20.713701 million in funding

Interim Chief Executive Officer Charlotte Leife has left the company

Sprint Bioscience AB (publ) Appoints Erik Kinnman as New CEO in Place of Charlotte Leife

New 90-day low: €0.63

Revenue beats expectations

Full year 2020 earnings released: kr2.02 loss per share (vs kr1.92 loss in FY 2019)

New 90-day low: €0.68

Third quarter 2020 earnings released: kr0.36 loss per share

CEO

Permanencia

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad